ReviewJournal of thoracic disease2025
Narrative review of the progress in the treatment of hemoptysis among patients with advanced lung cancer.
Review in Journal of thoracic disease, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background and Objective: Hemoptysis is a common clinical manifestation in patients with lung cancer, and severe hemoptysis can be life-threatening. Advanced lung cancer is associated with massive hemoptysis and involves a poor prognosis, but there is currently a lack of relevant diagnostic and treatment standards for this disease. This review examines the application of hemoptysis-related treatment measures in patients with advanced lung cancer, providing a reference for the selection of appropriate treatment strategies in clinical practice. Methods: A comprehensive literature search was conducted of the PubMed and Web of Science databases for studies published from January 1, 2000 to December 31, 2024. The search keywords included "lung cancer", "cancer of the lung", "hemoptysis", "bronchial artery embolization", and "bronchial arterial chemoembolization". Only studies on the treatment of hemoptysis in patients with advanced lung cancer that were published in peer-reviewed journals and in the English language were included. Key Content and Findings: Mild hemoptysis can be treated conservatively. For life-threatening hemoptysis, airway safety and hemodynamic stability should be first maintained. Depending on the condition, bronchial artery embolization, bronchial arterial chemoembolization, and other treatments can be used. When medication or endovascular treatment is ineffective and the condition stable, palliative resection surgery can be performed. To reduce the recurrence of hemoptysis, active etiological treatment should be carried out after hemostasis. Conclusions: Intravascular embolization has been proven to be an effective method for treating various types of hemoptysis, with high safety and efficacy. Accurately identifying and evaluating the degree of hemoptysis in patients with advanced lung cancer and developing personalized treatment plans are crucial for avoiding fatal outcomes, reducing hemoptysis recurrence, and improving prognosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.